Earnings summaries and quarterly performance for iRhythm Holdings.
Executive leadership at iRhythm Holdings.
Quentin Blackford
Detailed
President and Chief Executive Officer
CEO
CP
Chad Patterson
Detailed
Chief Commercial Officer
DW
Daniel Wilson
Detailed
Chief Financial Officer
MS
Mervin Smith
Detailed
Executive Vice President, Business Operations
MT
Mintu Turakhia
Detailed
Chief Medical Officer, Chief Scientific Officer, and EVP, Product Innovation
PM
Patrick Murphy
Detailed
Chief Business Officer and Chief Legal Officer
SS
Sumi Shrishrimal
Detailed
Executive Vice President, Chief Risk Officer
Board of directors at iRhythm Holdings.
Research analysts who have asked questions during iRhythm Holdings earnings calls.
DR
David Rescott
Baird
4 questions for IRTC
Also covers: HAE, INSP, LIVN +7 more
SK
Suraj Kalia
Oppenheimer & Co. Inc.
4 questions for IRTC
Also covers: ABT, AORT, ATRC +14 more
AG
Allen Gong
JPMorgan Chase & Co.
3 questions for IRTC
Also covers: ESTA, GEHC, GKOS +3 more
DR
David Roman
Goldman Sachs Group Inc.
3 questions for IRTC
Also covers: ABT, BAX, BDX +18 more
Kallum Titchmarsh
Morgan Stanley
3 questions for IRTC
Also covers: ATEC, AXNX, EMBC +5 more
MK
Macauley Kilbane
William Blair & Company
3 questions for IRTC
Also covers: CBLL, CVRX, GKOS +4 more
NT
Nathan Treybeck
Wells Fargo Securities
3 questions for IRTC
Also covers: ITGR, LMAT, NVRO +2 more
RN
Richard Newitter
Truist Securities
3 questions for IRTC
Also covers: AXNX, DXCM, GKOS +18 more
DS
David Saxon
Needham & Company
2 questions for IRTC
Also covers: ALC, ALGN, ATEC +11 more
JY
John Young
Canaccord Genuity - Global Capital Markets
2 questions for IRTC
Also covers: ANGO, CVRX, LUNG +2 more
Marie Thibault
BTIG
2 questions for IRTC
Also covers: ABT, ARAY, ATRC +15 more
Anthony Occhiogrosso
Citigroup Inc.
1 question for IRTC
Also covers: HAE
Bill Plovanic
Canaccord Genuity
1 question for IRTC
Also covers: ANGO, AORT, CBLL +7 more
BV
Brandon Vazquez
William Blair & Company, L.L.C.
1 question for IRTC
Also covers: ALGN, CBLL, CVRX +17 more
LL
Lilia-Celine Lozada
JPMorgan Chase & Co.
1 question for IRTC
Also covers: ATRC, BVS, CBLL +4 more
PB
Philippe Belamant
Truist Securities
1 question for IRTC
Sam Eiber
BTIG, LLC
1 question for IRTC
Also covers: AIRS, APYX, EMBC +6 more
William Plovanic
Canaccord Genuity
1 question for IRTC
Also covers: ATRC, CBLL, CVRX +9 more
Recent press releases and 8-K filings for IRTC.
iRhythm Technologies Provides 2026 Financial Guidance and Strategic Updates
IRTC
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- iRhythm Technologies expects revenue of $870-$880 million in 2026, representing 17%-18% growth over the anticipated $740 million+ revenue for 2025, and projects Adjusted EBITDA of 11.5%-12.5% for 2026. The company achieved profitability from an adjusted EBITDA perspective and became free cash flow positive for the first time in 2025.
- The company holds 72% market share in the long-term cardiac monitoring (LTCM) space and 15% market share in the mobile cardiac telemetry (MCT) market, which represents a $500 million market opportunity. A new MCT product launch is anticipated in 2027 to enhance competitiveness.
- iRhythm is expanding into the undiagnosed, asymptomatic population, identifying a near-term opportunity of 30 million tests globally, including 27 million undiagnosed individuals in the U.S.. Over one-third of their business now comes through the primary care channel.
- The company leverages AI, including an investment in Lucem, to proactively identify patients with arrhythmias with over 85% accuracy. They are also expanding internationally, currently operating in six countries with less than 1% market share.
Jan 12, 2026, 4:15 PM
IRTC Provides 2025 and 2026 Financial Guidance and Strategic Updates
IRTC
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- iRhythm Technologies anticipates full year 2025 revenue of $740+ million and projects 2026 revenue between $870 million and $880 million.
- The company expects to achieve an Adjusted EBITDA margin of 8.25% - 8.75% for 2025 and 11.5% - 12.5% for 2026.
- iRhythm holds a 72% market share in U.S. Long-Term Continuous Monitoring (LTCM) and 15% in Mobile Cardiac Telemetry (MCT), addressing 27+ million potential patients in the U.S..
- Strategic growth initiatives include international expansion into the UK, prioritized EU countries, and Japan, along with the development of a next-gen Zio MCT (510(k) submitted 3Q25) and initial commercial pilots in obstructive sleep apnea.
- 2025 is anticipated to be free cash flow positive for the first time in the company's history.
Jan 12, 2026, 4:15 PM
iRhythm Technologies Provides 2025 Financial Highlights and 2026 Guidance
IRTC
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- iRhythm Technologies expects to deliver more than $740 million in revenue for 2025, marking the first time the company will be profitable (adjusted EBITDA positive) and free cash flow positive in its history.
- For 2026, the company forecasts revenue between $870 million and $880 million, representing 17%-18% growth, and anticipates an adjusted EBITDA margin of approximately 11.5%-12.5%.
- The company is expanding into new markets, with over 1/3 of its business now coming through the primary care channel , and is developing a new MCT product expected to launch in 2027 that will monitor for up to 21 days.
- iRhythm sees significant growth opportunities in the undiagnosed population (an estimated 27 million people in the U.S. alone) and international markets where it currently holds less than 1% market share.
Jan 12, 2026, 4:15 PM
iRhythm Reports Strong 2025 Financial Performance and Provides 2026 Guidance
IRTC
Guidance Update
Revenue Acceleration/Inflection
Product Launch
- iRhythm expects to deliver over $740 million in revenue for 2025, exceeding its high-end guidance, and projects $870-$880 million in revenue for 2026, representing 17%-18% growth.
- The company anticipates achieving profitability (adjusted EBITDA) and positive free cash flow for the first time in its history in 2025, with an expected adjusted EBITDA margin of 11.5%-12.5% in 2026.
- iRhythm is expanding its market reach by moving into primary care, which now accounts for over one-third of its business, and is leveraging AI with partners to proactively identify undiagnosed arrhythmia patients with over 85% accuracy.
- A new Zio AT product for the Mobile Cardiac Telemetry (MCT) market, offering 21 days of monitoring, is on file with the FDA and is expected to launch in 2027, a timeline influenced by FDA cybersecurity questions and the success of the current AT product.
Jan 12, 2026, 4:15 PM
iRhythm Technologies Provides Preliminary Q4 2025 Highlights and 2026 Outlook
IRTC
Guidance Update
Revenue Acceleration/Inflection
- iRhythm Technologies anticipates full year 2025 revenue to exceed the high end of its previously stated guidance of $740 million, driven by record revenue unit volume during the fourth quarter 2025.
- For full year 2026, the company expects revenue of approximately $870 million to $880 million, representing approximately 17% to 18% year-over-year growth, and an anticipated adjusted EBITDA margin of approximately 11.5% to 12.5%.
- 2025 was a transformative year for iRhythm, marked by over 25% year-over-year revenue growth and achieving free cash flow positivity for the first time in company history.
- The company is well-positioned to accelerate leadership in 2026 with growth catalysts including deepening penetration in primary care, momentum in mobile cardiac telemetry, and expansion into adjacent markets.
Jan 12, 2026, 12:30 PM
iRhythm Technologies Discusses 2025 Performance, 2026 Outlook, and Product Pipeline
IRTC
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- iRhythm (IRTC) maintains a strong market position with over 70% share in long-term continuous monitoring (LTCM) and approximately 15% share in mobile cardiac telemetry (MCT).
- The company expects an 8% increase in Medicare rates for LTCM in 2026, which represents 25% of its revenue, with commercial rates anticipated to remain stable.
- Revenue acceleration in 2025 was driven by strong Zio AT performance, growth in the Innovative Channel, and core Zio Monitor business acceleration, with over 50% of volume now processed through EHR integrations, yielding a consistent 25% uplift in integrated accounts.
- iRhythm submitted a 510(k) for its next-generation Zio MCT device in early September, which will offer 21 days of wear, though it is not expected to meaningfully impact 2026 revenue and is projected as a 2027 driver.
- For fiscal year 2026, the company anticipates revenue growth of 16%-18% and expects to be free cash flow positive for the first time in 2025, targeting 15% adjusted EBITDA by 2027.
Dec 4, 2025, 2:10 PM
iRhythm Technologies Reviews Strong 2025 Performance and Provides 2026 Outlook
IRTC
Revenue Acceleration/Inflection
Guidance Update
Product Launch
- iRhythm Technologies reported a "phenomenal year" in 2025 with accelerated revenues, attributing growth to strong Zio AT performance, expansion in the innovative channel, and core Zio Monitor business acceleration through EHR integration and primary care penetration.
- The company provided a preliminary 2026 revenue growth outlook of 16% to 18%, noting this reflects difficult comparable periods following 2025's acceleration.
- The next-generation mobile cardiac telemetry (MCT) product, Zio MCT, submitted for 510(k) FDA clearance in early September, is expected to be a 2027 driver rather than a meaningful contributor to 2026 revenue.
- For 2026, Medicare rates for long-term continuous monitoring (LTCM) are expected to increase by 8%, though Medicare accounts for only 25% of the company's revenue.
- iRhythm achieved free cash flow positive status for the first time in 2025 and is on track for a 15% adjusted EBITDA target by 2027.
Dec 4, 2025, 2:10 PM
iRhythm Discusses 2025 Performance, 2026 Outlook, and Product Development
IRTC
Revenue Acceleration/Inflection
Guidance Update
Product Launch
- iRhythm reported a "phenomenal year" in 2025 with revenue acceleration, driven by strength in its Zio AT product, competitive disruption, growth in the Innovative Channel, and increased EHR integration.
- For 2026, Medicare rates for Long-Term Continuous Monitoring (LTCM) are expected to increase by 8%, while Mobile Cardiac Telemetry (MCT) rates are projected to slightly decrease.
- The company provided a preliminary outlook for 16%-18% growth in 2026, acknowledging difficult comparisons from 2025.
- iRhythm submitted its next-generation Zio MCT device to the FDA via a 510(k) in early September 2025, but it is not expected to meaningfully contribute to 2026 revenue.
- iRhythm anticipates being free cash flow positive for the first time in 2025 and is on pace to achieve a 15% adjusted EBITDA target in 2027.
Dec 4, 2025, 2:10 PM
iRhythm Discusses Market Growth, Product Pipeline, and 2026 Outlook
IRTC
Guidance Update
Product Launch
New Projects/Investments
- iRhythm's CFO, Dan Wilson, highlighted the company's transition to a profitable growth company. The long-term continuous monitoring market, where iRhythm holds a low 70% share, is growing at high teens % year over year, with iRhythm gaining 1-2 points of market share.
- Key growth drivers include the increasing adoption in primary care, which now accounts for 30% of Zio XT patch usage, up from 20%. The company also benefits from the Pulsed Field Ablation trend and over 50% of its volume coming through EHR integration.
- The Zio MCT product was submitted to the FDA in early September but is not expected to contribute to 2026 revenue. Positively, Medicare rates for Zio Monitor are increasing by approximately 8% for next year, impacting 25% of the company's revenue.
- iRhythm has expanded its international presence, launching in five new markets in the last 12-14 months, with significant contributions anticipated from 2027 and beyond. The company is also investing in a multi-vitals platform for future opportunities such as sleep apnea.
- For 2026, iRhythm is comfortable with preliminary revenue guidance in the 16%-18% range, emphasizing a "thoughtful" approach to guidance and a commitment to 400 basis points of adjusted EBITDA expansion year to year.
Dec 3, 2025, 6:00 PM
iRhythm Technologies Discusses 2026 Outlook and Strategic Initiatives
IRTC
Guidance Update
Product Launch
New Projects/Investments
- iRhythm Technologies provided preliminary 2026 revenue guidance, indicating comfort with street numbers in the 16%-18% growth range, with less predictable areas like the Innovative Channel considered potential upside.
- The company continues to lead the long-term continuous monitoring market, which is growing at high teens percent year-over-year, and is gaining 1-2 points of market share. A significant driver is the shift to primary care, now accounting for 30% of Zio XT patch usage.
- Zio MCT was submitted to the FDA in early September 2025, but is not expected to contribute to 2026 revenue. Medicare rates for long-term continuous monitoring (Zio Monitor) are projected to increase by approximately 8% in 2026.
- iRhythm is expanding internationally into five new markets and investing in a multi-vitals platform for future opportunities, particularly in sleep apnea, though these are mid to longer-term drivers.
Dec 3, 2025, 6:00 PM
Quarterly earnings call transcripts for iRhythm Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more